Mithra Announces Information on the Total Number of Voting Rights (Denominator)
26 Giugno 2023 - 5:45PM
Mithra Announces Information on the Total Number of Voting Rights
(Denominator)
Mithra Announces
Information on the Total Number of Voting Rights
(Denominator)
Liege,
Belgium,
26 June
2023
–
17:45
CEST – Mithra
(Euronext Brussels: MITRA), a company dedicated to Women’s Health,
today announces that, following the drawdown of the third tranche
by the Company under the loan facility concluded with funds managed
by Highbridge Capital Management, LLC (“Highbridge“) and funds
managed by Whitebox Advisors, LLC (“Whitebox“, and together with
Highbridge, each a “Lender”), a third portion of the commitment
fee, representing 25% of the aggregate amount of EUR 2,911,372.65,
has been settled through the issuance of 91,663 new shares of the
Company at a price per share of EUR 7.9401.
As a reminder, a first portion representing 65%
of the commitment fee was already settled in shares at the time of
the first drawing and the second portion representing a further 10%
of the commitment fee was already settled in shares at the time of
the second drawing.
In accordance with article 15 of the Belgian Act
of 2 May 2007 on the disclosure of major participations in issuers
of which shares are admitted to trading on a regulated market and
regarding miscellaneous provisions, following this capital
increase’s completion Mithra now has 58,587,058 outstanding shares
carrying voting rights (against 53,527,729 outstanding shares
carrying voting rights previously).
Therefore, Mithra publishes the following
updated information:
- Capital: EUR
42,891,360.13
- Total number of
securities carrying voting rights: 58,587,058 (all ordinary
shares)
- Total number of
voting rights (= denominator): 58,587,058 (all relating to ordinary
shares)
- Number of
outstanding rights to subscribe to securities carrying voting
rights:
- Pursuant to the
share option plan of 5 November 2018: 1,394,900 subscription rights
giving right to 1,394,900 ordinary shares
- Pursuant to the
share option plan of 22 July 2020: 690,000 subscription rights
giving right to 720,571 ordinary shares
- Pursuant to the
share option plan granted to the lending shareholders of 7
September 2020: 300,000 subscription rights giving right to 313,292
ordinary shares
- Pursuant to the
share option plan of 20 November 2020: 390,717 subscription rights
giving rise to 390,717 ordinary shares
For more information, please
contact:
Mithra Pharmaceuticals
SADavid Horn SolomonChief Executive
Officerinvestorrelations@mithra.com |
Investor &
media relationsChris MaggosCohesion
Bureauchris.maggos@cohesionbureau.com +41 79 367 6254 |
About
Mithra
Mithra Pharmaceuticals SA (Euronext: MITRA) is a
Belgian biopharmaceutical company dedicated to transforming Women’s
Health by offering new choices through innovation, with a
particular focus on contraception and menopause. Mithra’s goal is
to develop products offering better efficacy, safety and
convenience, meeting women’s needs throughout their life span.
Mithra explores the potential of the unique native estrogen
estetrol in a wide range of applications in women health and
beyond. After having successfully launched the first estetrol-based
product in 2021, the contraceptive pill Estelle®, Mithra is now
focusing on its second product Donesta®, the next-generation
hormone therapy. Mithra also offers partners a complete spectrum of
solutions from early drug development, clinical batches and
commercial manufacturing of complex polymeric products (vaginal
ring, implants) and complex liquid injectables and biologicals
(vials, pre-filled syringes or cartridges) at its technological
platform Mithra CDMO. Active in more than 100 countries around the
world, is headquartered in Liège, Belgium. www.mithra.com
ESTELLE®, and DONESTA® are registered trademarks
of Mithra Pharmaceuticals or one of its affiliates.
Important information
The contents of this announcement include
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the words
"believes", "estimates," "anticipates", "expects", "intends",
"may", "will", "plans", "continue", "ongoing", "potential",
"predict", "project", "target", "seek" or "should", and include
statements the Company makes concerning the intended results of its
strategy. By their nature, forward-looking statements involve risks
and uncertainties and readers are cautioned that any such
forward-looking statements are not guarantees of future
performance. The Company's actual results may differ materially
from those predicted by the forward-looking statements. The Company
undertakes no obligation to publicly update or revise
forward-looking statements, except as may be required by law.
Subscribe to our mailing list on investors.mithra.com to receive
our press releases by email or follow us on our social media
:Linkedin • Twitter • Facebook |
- 2023-06-26_Mithra HB-WB 3rd Tranche Access Fee_FR
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Mithra Pharmaceuticals (EU:MITRA)
Storico
Da Mag 2023 a Mag 2024